Teva breached antitrust rules over Copaxone, says EU

11-10-2022

Sarah Speight

Teva breached antitrust rules over Copaxone, says EU

JHVEphoto / Shutterstock.com

European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.


Teva, EU, EC, European Commission, Copaxone, patents, generics, antitrust, anti-competition

LSIPR